Telix Pharmaceuticals Ltd — Capital/Financing Update 2017

Nov 13, 2017

Notice

Notice reference number: 1281.17.11

What’s this about?

Notice date: 14/11/2017 Effective date: 14/11/2017

==> picture [507 x 108] intentionally omitted <==

----- Start of picture text -----

 ASX Trade ASX 24 ASX TECH
 Trading Clearing Settlement ALC ASX NET
Operations Technology Market Data Rules Compliance Risk  Other
Title
----- End of picture text -----

Telix Pharmaceuticals Limited – Admission and Commencement of Official Quotation

Description

Telix Pharmaceuticals Limited (Company) is expected to be admitted to the Official List of ASX Limited (ASX) on Wednesday, 15 November 2017.

Official quotation of the Company’s securities is expected to commence at 12:00 pm AEDT on Wednesday, 15 November 2017 on a deferred settlement basis. The Company is expected to raise $55.05 million by the offer of 77,000,000 ordinary shares at $0.65 per share under a prospectus dated 16 October 2017.

Quoted Securities: 90,076,922 fully paid ordinary shares ASX Code: TLX Time: 12:00 pm AEDT Date: Wednesday, 15 November 2017 ASX Trade Abbreviation: TELIXPHARM ISIN: AU000000TLX2 Home Branch: Melbourne Industry Classification: Pending Registered Office: Suite 401, 55 Flemington Road North Melbourne VIC 3051 Phone: 0449 148 448 Company Secretary: Melanie Farris Share Registry: Link Market Services Level 1, 680 George Street Sydney NSW 2000 Balance Date: 31 December CHESS: Participating. The Company will also operate an issuer sponsored sub-register. Place of Incorporation: Victoria, Australia

1/3

ASX Notice

(continued)

Dividend Policy:	See page 19 of the Company’s prospectus.
Activities:	Developing and commercialising molecularly targeted radiation products for the treatment
	of cancer.
ASX Restricted Securities:	67,391,913 fully paid ordinary shares escrowed for 24 months from the date of quotation.
	37,031,165 fully paid ordinary shares escrowed for 12 months from the date of issue being
	until 15 January 2018.
	2,937,500 fully paid ordinary shares escrowed for 12 months from the date of issue being
	until 5 March 2018.
	2,475,000 options exerciseable at 85 cents expiring 15 October 2021 escrowed for 24 months
	from the date of quotation.
Securities not quoted:	Nil.

Indicative key dates

The following timetable is for the deferred settlement trading in the Company’s securities.

Date	Event
Wednesday 15 November 2017	Company admitted to the official list of ASX Commencement of Official Quotation on a deferred settlement basis – 12:00pm AEDT (ASX Code: TLX)
Thursday 16 November 2017	Holding statements sent to successful applicants Last day for deferred settlement trading
Friday 17 November 2017	First day of trading on a normal (T+2) basis (ASX Code: TLX)
Tuesday 21 November 2017	Settlement of all on-market trades conducted on a deferred settlement basis from 15 to 16 November 2017, and first settlement of trades conducted on a T+2 basis

What do I need to do and by when?

For further details, please refer to the Company’s prospectus dated 16 October 2017.

Need more information?

For further details, please refer to the Company’s prospectus dated 16 October 2017.

Issued by James Gerraty

4B

Contact Details

(03) 9617 7842 5 Disclaimer

2/3

ASX Notice

(continued)

3/3